The pharmaceutical company Galichpharm JSC (Lviv) plans to increase sales by 15% by the end of 2025, according to a report posted on its website.
According to the report, in the first nine months of 2025, Galichpharm produced 4.753 million packages of finished medicines worth UAH 904.94 million.
The average cost of one package of manufactured medicines in the form of injections was UAH 132.24, infusions – UAH 32.35, liquids and syrups – UAH 67.9, and tablets – UAH 22.24.
The company’s revenue for January-September reached UAH 252.449 million.
In addition, the company reports that exports accounted for 9.13% of total sales, and its products were supplied abroad for more than UAH 23 million. The company exports to the markets of Kazakhstan, Georgia, Uzbekistan, Latvia, and other countries.
According to the company’s estimates, Galichpharm ranks fifth in terms of retail sales in monetary terms for the first nine months of 2025, with a market share of 1.3%.
As reported, at the end of 2024, Galichpharm reduced its net profit by 39% compared to 2023, to UAH 13.705 million, while in 2023 this figure was UAH 22.52 million.
As reported, the investment company Sky Development won an open auction organized by the Deposit Guarantee Fund and acquired the rights to claim the insolvent JSC Bank Finance and Credit under ten loan agreements with leading Ukrainian pharmaceutical companies: JSC Galichpharm and JSC Kyivmedpreparat. According to Sky Development, the total amount of its claims exceeds UAH 3.5 billion.
For their part, Kyivmedpreparat and Galichpharm stated that the information disseminated by Sky Development is “unreliable, manipulative, and shows signs of deliberate discrediting of the companies’ activities.” In particular, both companies denied the existence of “multibillion-dollar debts” to Sky Development. The pharmaceutical companies regarded the statements of Sky Development LLC as “an attempt to illegally create non-existent creditor debt for the purpose of a possible raider takeover of the companies.”
